import type { LearnArticle } from "../../types";

const DATE = "2026-08-25";

export const article: LearnArticle = {
  vertical: "weight-loss",
  slug: "tirzepatide-in-texas",
  title: "Tirzepatide in Texas: Telehealth Access and Rules",
  h1: "Tirzepatide in Texas: statewide telehealth access",
  description:
    "Texas adults can be evaluated for tirzepatide online under Chapter 111 telemedicine rules. Dual-agonist basics and what a provider checks first.",
  keywords: [
    "tirzepatide texas",
    "tirzepatide houston",
    "tirzepatide doctor houston",
    "tirzepatide online",
    "glp 1 in texas",
    "dual agonist weight loss",
  ],
  cluster: "programs-local",
  relatedSlugs: [
    "tirzepatide-in-houston",
    "tirzepatide-online",
    "glp-1-in-texas",
    "glp-1-in-houston",
    "semaglutide-in-texas",
    "semaglutide-in-houston",
    "stopping-tirzepatide",
    "foods-to-avoid-on-tirzepatide",
    "glp-1-doctor",
  ],
  moneyPageHrefs: ["/weight-loss", "/tirzepatide", "/glp-1", "/glp-1-houston"],
  datePublished: DATE,
  dateModified: DATE,
  sources: [
    {
      label: "Texas Occupations Code Chapter 111. Telemedicine and telehealth.",
      href: "https://statutes.capitol.texas.gov/Docs/OC/htm/OC.111.htm",
    },
    {
      label:
        "Texas Administrative Code, Title 22, Part 9, Chapter 174: Telemedicine practice standards and prescribing.",
      href: "https://texreg.sos.state.tx.us/public/readtac$ext.ViewTAC?tac_view=4&ti=22&pt=9&ch=174",
    },
    {
      label:
        "Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022.",
      href: "https://doi.org/10.1056/NEJMoa2206038",
    },
    {
      label:
        "Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025.",
      href: "https://doi.org/10.1056/NEJMoa2416394",
    },
    {
      label: "Zepbound (tirzepatide) prescribing information via DailyMed.",
      href: "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b",
    },
    {
      label:
        "U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss.",
      href: "https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss",
    },
  ],
  faqs: [
    {
      question: "Can Texas residents get tirzepatide through telehealth?",
      answer:
        "Yes, when a clinician licensed to treat patients in Texas completes a proper evaluation. Chapter 111 and the Texas Medical Board's rules hold that online visit to the same standard of care as an in-person one. Beema Health serves all 50 states including Texas, USA only, and completing intake never guarantees a prescription.",
    },
    {
      question: "Is tirzepatide different from semaglutide?",
      answer:
        "Mechanically, yes. Semaglutide activates the GLP-1 receptor. Tirzepatide activates both GLP-1 and GIP receptors, which is why it is described as a dual agonist. That difference does not automatically make it the right choice for a given person, and a clinician weighs history, other medicines, and tolerance rather than mechanism alone.",
    },
    {
      question: "Do I need to be in Houston, Dallas, or Austin?",
      answer:
        "No. Telehealth access under Texas rules depends on where the patient is located and where the clinician is licensed, not on proximity to a metro. Rural Texas residents face the same intake as someone in Harris County. There is no Beema Health clinic in any Texas city to visit.",
    },
    {
      question: "What did the head-to-head trial actually show?",
      answer:
        "SURMOUNT-5 compared tirzepatide with semaglutide in adults with obesity and reported greater mean weight reduction with tirzepatide. That is one trial in a selected population reporting averages. It is not a personal prediction, and it does not override a clinician's judgment about which medicine suits your history.",
    },
    {
      question: "How should tirzepatide be stored in a Texas summer?",
      answer:
        "Follow the storage section on the carton you were dispensed, which sets a refrigerated range and a bounded room-temperature window. A parked car in Texas heat exceeds that window quickly. Do not leave medication in a vehicle, and ask the dispensing pharmacy if a shipment sat outside on a hot day.",
    },
    {
      question: "Is compounded tirzepatide the same as the branded product?",
      answer:
        "No. Compounded tirzepatide is not FDA-approved and is considered only when legally available and clinically appropriate. It should not be assumed identical to a branded FDA-approved tirzepatide product. FDA has warned separately about unapproved GLP-1 products sold outside the licensed prescriber and pharmacy path.",
    },
  ],
  sections: [
    {
      id: "access",
      heading: "What Texas law requires before anyone prescribes",
      body: [
        "Texas does not treat an online visit as a lesser visit. Chapter 111 of the Occupations Code and Chapter 174 of the Texas Administrative Code set the standard of care for telemedicine at the same level as in-person care and govern how a prescription may follow. The practical consequence is simple: a real evaluation happens first, or the encounter is not legitimate care.",
        "Where you live inside Texas does not change that. Someone searching from Houston and someone searching from a town outside Lubbock go through the same intake, because the rule keys on patient location and clinician licensure, not on driving distance.",
      ],
    },
    {
      id: "dual-agonist",
      heading: "What the dual-agonist design actually means",
      body: [
        "Tirzepatide activates two incretin receptors, GLP-1 and GIP, where semaglutide activates one. Both slow gastric emptying and reduce appetite. The second pathway is the reason tirzepatide is discussed separately rather than as another semaglutide, and it is also part of why the side-effect conversation is not identical between the two.",
        "Gastrointestinal effects remain the dominant adverse-reaction group for this class. Nausea, vomiting, diarrhea, and constipation cluster around dose increases. The labeled titration schedule exists to manage that, which is why stepping up faster than the label is not a shortcut.",
      ],
      bullets: [
        "GLP-1 receptor: appetite and gastric-emptying effects shared with semaglutide",
        "GIP receptor: the second incretin pathway unique to tirzepatide among approved options",
        "Titration: stepwise by label, adjusted by a clinician rather than by the patient",
      ],
    },
    {
      id: "evidence",
      heading: "What the trials reported",
      body: [
        "SURMOUNT-1 studied tirzepatide once weekly in adults with obesity and reported substantial mean weight reduction against placebo over 72 weeks. SURMOUNT-5 then compared tirzepatide directly with semaglutide in adults with obesity and reported greater mean reduction with tirzepatide.",
        "Both numbers are population averages from controlled trials with structured follow-up. They describe what happened to groups, not what will happen to you, and they were produced in studies that included lifestyle counseling rather than medication alone. A clinician deciding between molecules is weighing your history, not a headline.",
      ],
    },
    {
      id: "heat-and-storage",
      heading: "Heat, dehydration, and storage in a Texas climate",
      body: [
        "The class carries a warning that vomiting and diarrhea can cause dehydration and, in reported cases, acute kidney injury. Texas summers add fluid loss independent of the medication, so a dose increase during a stretch of extreme heat leaves less margin. That is worth raising at a follow-up rather than absorbing quietly.",
        "Storage matters for the same reason. Labeled ranges assume refrigeration or a limited room-temperature window, and a closed vehicle exceeds both quickly. Read the storage section on the carton you actually received, since presentations differ.",
      ],
    },
    {
      id: "beema-status",
      heading: "What Beema Health offers Texas patients today",
      body: [
        "Beema Health is a cash-pay telehealth program for medical weight loss, available to adults in all 50 states including Texas. A licensed provider reviews intake and decides independently whether compounded semaglutide, compounded tirzepatide, or no medication is appropriate. Compounded tirzepatide is not FDA-approved and is considered only when legally available and clinically appropriate. Prescribing is never guaranteed.",
        "Beema Health does not sell Zepbound or Mounjaro. Those brand names appear here because their prescribing information is the public source for labeled facts about tirzepatide. Current pricing lives on the tirzepatide program page, which is the authoritative source rather than any figure quoted in an article.",
      ],
    },
    {
      id: "next-steps",
      heading: "Where to read next",
      body: [
        "For the process rather than the geography, the [tirzepatide online](/learn/weight-loss/tirzepatide-online/) guide covers what a lawful telehealth path looks like. For Houston specifically, see [tirzepatide in Houston](/learn/weight-loss/tirzepatide-in-houston/). For the other molecule in Texas, see [semaglutide in Texas](/learn/weight-loss/semaglutide-in-texas/). Live cash-pay plans: [compounded tirzepatide](/tirzepatide/).",
      ],
    },
  ],
  ctaId: "learn_weight_loss",
};
